Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06623422
Title	A Study of Pembrolizumab (MK-3475) With or Without V940 in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Acronym	V940-009/INTerpath-009
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Merck Sharp & Dohme LLC
Indications	lung non-small cell carcinoma
Therapies	Paclitaxel mRNA-4157 + Pembrolizumab Gemcitabine Carboplatin Pembrolizumab Pemetrexed Disodium Cisplatin
Age Groups:	senior \| adult
Covered Countries	USA \| ISR \| GBR \| CAN \| AUS \| ARG